ALung Secures $2.5 Million

Respiratory Support Company Announces Financing from Angels to Drive Clinical
Trials in India and Germany

PITTSBURGH, Oct. 6 /PRNewswire/ -- ALung Technologies, Inc. today announced
that the company has raised $2.5 million from a group of current ALung
investors. The investment will allow the company to fund its Indian and
German clinical trials as well as support working capital needs. ALung is the
leading developer of a device designed to replace or supplement ventilators in
hospitals. The company's Hemolung device is expected to positively impact
clinical outcomes and reduce the length of hospital stays by several days,
resulting in a significant reduction of total medical costs for providers and
insurers.

The Hemolung System is designed to remove carbon dioxide and deliver oxygen
directly to the patient's blood via a small catheter, inserted into the
jugular or femoral vein, similar to acute kidney dialysis. This treatment is
expected to provide a significant benefit over intubation and mechanical
ventilation, in that it will allow the patient to talk and eat, and avoid
sedation, while giving the lungs the opportunity to heal.

"ALung has the potential to improve care greatly for the target patient group
over the current methods used in Intensive Care Units (ICUs), achieving both
improvements in clinical outcomes and major savings in cost of care," said
Peter M. DeComo, ALung's Chairman and CEO and an investor in the company.
"Today's health care community is focused on the principal goals of reducing
health care costs and improving patient care. Our device - which can eliminate
a very large expenditure of money and human resources while improving outcomes
for patients - will therefore be extremely relevant."

Currently 450,000 patients in the U.S. are ventilated each year for temporary,
acute or acute-on-chronic respiratory failure. It is anticipated that the
clinical trials will demonstrate that the Hemolung System can replace or
supplement this form of ventilation. With intensive care unit (ICU) care
estimated at $5-7,000 per day, Hemolung is expected to reduce hospital costs
through its ability to reduce ICU length of stay. Further cost savings are
expected to be realized through the elimination of sedation costs and a
reduction in adverse outcomes such as ventilator acquired pneumonia (VAP) -
estimated at greater than $125,000 per incident. VAP represents the most
common and deadly hospital acquired condition (HAC) with approximately 25
percent of all ventilator patients developing the condition. (ref: Society of
Critical Care Medicine).

"We are very enthusiastic regarding the positive outcome of our near-term
clinical trials," said Mr. Nick Kuhn, Chief Operating Officer of ALung, "The
completion of our eight animal studies, as well as our in vitro testing, have
resulted in excellent results, indicating that the upcoming Hemolung human
clinical trials should yield very positive results."

ALung is moving forward with a five patient "First in Man" trial in India on
the Hemolung
System, and a 20 patient pilot trial in Germany. Both trials are expected to
begin in the fourth quarter of 2009.

About ALung Technologies
ALung Technologies, Inc. is commercializing artificial lung devices for the
treatment of acute and chronic respiratory disorders. The company's Hemolung
System, designed to replace or supplement the use of ventilators for patients
with acute respiratory failure, is scheduled to begin clinical trials in the
fall of 2009. Learn more about ALung and Hemolung at www.alung.com.

SOURCE ALung Technologies, Inc.

Jennifer Bannan, Zer0 to 5ive, +1-412-580-3675, jen@0to5.com